Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?
News & Analysis: Vertex Pharmaceuticals
Biogen is more profitable, more innovative, and its stock may be undervalued to boot.
Elements from the past, present, and future are reasons to be optimistic about this biotech star.
Even if the market goes down, these investing options should go up.
Don't worry. Get busy.
They have one big thing in common: great growth prospects.
These two companies will keep competitors at bay for many years to come.
Revenue is climbing at these biotech companies. And one of them is waiting for what could be an historic product approval.
One big biotech and two small biotechs especially stand out as attractive picks.
This successful biotech has two big things going for it.